UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act. | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act. | |
| Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of Class | Trading Symbol(s) | Exchange Name |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
On Thursday, June 11, 2026, at 10:00 a.m. Eastern Time, by means of an online meeting platform, Nuvectis Pharma, Inc. (the “Company”) held its 2026 Annual Meeting (the “Annual Meeting”).
The Company's Definitive Proxy Statement on Schedule 14A (the “Proxy”), filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 27, 2026, inadvertently misstated the total number of shares of common stock outstanding as of the record date of April 13, 2026, as 27,668,036. The correct number of shares of common stock outstanding as of the record date was 26,614,628. This correction does not affect the validity of any votes cast at the Annual Meeting or the outcome of any proposal voted upon.
Stockholders representing 16,193,686, or 60.8%, of the 26,614,628 shares of common stock outstanding on the record date of April 13, 2026, were present in person or by proxy, constituting a quorum under applicable law. Proxies were solicited by the Company pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended. Each of the proposals below is described in detail in the Company’s Proxy for the Annual Meeting, filed with the SEC on April 27, 2026. At the Annual Meeting, all of the proposals were approved.
The results are as follows:
Proposal 1
The vote with respect to the election of the Class I director to hold office until the 2029 annual meeting was as follows:
| Director | Votes For | Votes Against | Abstentions / Votes Withheld | Broker Non-Votes | ||||
| Ron Bentsur | 8,354,838 | 391,265 | 216 | 7,447,367 |
Proposal 2
The vote with respect to the ratification of Kesselman & Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was as follows:
| Votes For | Votes Against | Abstentions / Votes Withheld | Broker Non-Votes | |||
| 15,662,222 | 10,574 | 520,890 | - |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Nuvectis Pharma, Inc. | ||
| (Registrant) | ||
| Date: June 12, 2026 | ||
| By: | /s/ Ron Bentsur | |
| Ron Bentsur | ||
| Chairman, Chief Executive Officer and President | ||